We are hereby submitting audited standalone and consolidated financial results of the Company for the quarter ended 31st March, 2026
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts more than Nifty Microcap 250 and 9.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kilitch Drugs reported strong Q4 FY26 results with standalone net sales of Rs 7,196.88 lakhs (up 28% YoY) and consolidated net sales of Rs 8,960.27 lakhs (up 46% YoY). For the full year, consolidated revenue grew 18.7% to Rs 23,547.49 lakhs while PAT increased 18.3% to Rs 2,950.03 lakhs. The company issued bonus shares in 1:1 ratio during Q4. Auditors issued an unmodified (clean) opinion on both standalone and consolidated financials. Capital expenditure was substantial at Rs 9,950.74 lakhs, funded through increased borrowings. Trade receivables grew significantly by Rs 3,753.35 lakhs, outpacing revenue growth. One foreign subsidiary (Kilitch Estro Biotech PLC) remains unaudited as per management certification.
Positive Q4 and full-year performance with revenue and profit growth; however, the sharp increase in borrowings and trade receivables may raise concerns about working capital management and financial leverage. The clean audit opinion is a positive signal for investors.